Recombinant Anti-CD28 x Anti-CD40 Bispecific Antibody (scFv-IgG) (BSSG-056)

Recombinant Anti-CD28 x Anti-CD40 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD28 antibody variable domain are respectively connected to the N terminus of the anti-CD40 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can increase T-cell proliferation, induce DC maturation and prime efficacy of cytotoxic T cells. It is designed for the research of Acute myeloid leukaemic (AML) therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CD40

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Acute myeloid leukaemic (AML)

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CD40

Gene ID

958

UniProt ID

P25942

Alternative Names

CD40 molecule; CD40; p50; Bp50; Cluster of differentiation 40; CDW40; TNFRSF5; Tumor necrosis factor receptor superfamily member 5

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD28 x Anti-CD40 Bispecific Antibody (scFv-IgG) (BSSG-056). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD28 x Anti-CD40 Bispecific Antibody (scFv-IgG) (CAT#: BSSG-056)

Specifications

Targets

Customer Reviews and Q&As